Key result
The ACCOMPLISH trial is designed to randomize 12,600 hypertensive patients to compare amlodipine/benazapril versus benazapril/hydrochlorothiazide on cardiovascular mortality and morbidity over 5 years.
Why the study?
Does amlodipine/benazapril reduce cardiovascular mortality and morbidity compared to benazapril/hydrochlorothiazide in high-risk hypertensive patients?
RCT (n=12,600)
blinded
randomized
Yes
Does amlodipine/benazapril reduce cardiovascular mortality and morbidity compared to benazapril/hydrochlorothiazide in high-risk hypertensive patients?
The ACCOMPLISH trial is designed to compare the effects of amlodipine/benazapril versus benazapril/hydrochlorothiazide on cardiovascular outcomes in high-risk hypertensive patients.
Answers are grounded in this paper and cite their sources.
Supports initial CCB-ACEI combinations in high-risk hypertension; extends evidence favoring this pairing over diuretic-based regimens.
Reducing blood pressure (BP) to target levels is a major priority in preventing clinical events in hypertension. Typically this requires more than one drug, and recent guidelines on hypertension management therefore recommend starting with combination treatment in many patients. Diuretics have often been part of such therapy, usually paired with angiotensin converting enzyme (ACE) inhibitors or similar agents; but calcium channel blockers are also highly efficacious in reducing BP when combined with ACE inhibitors. In addition, these drug classes, separately and in combination, appear to have vasculoprotective properties. Because the primary goal of treating hypertension is to enhance survival and reduce cardiovascular outcomes, the Rationale and Design of Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) trial is designed as the first blinded and randomized study to prospectively compare the effects on these endpoints of two antihypertensive combinations, benazapril/hydrochlorothiazide (force titrated to 40/12.5 mg) and amlodipine besylate/benazapril (force titrated to 5/40 mg). The doses can be further titrated to 40/25 mg or 10/40 mg, and other classes of drugs can be added as needed for optimal BP control. The primary study endpoint is a composite of cardiovascular mortality and morbidity. The study will be performed in hypertensive patients (systolic BP > or = 160 mm Hg or currently on antihypertensive therapy) with risk factors for cardiovascular events (prior events, target organ damage, kidney disease, or diabetes). A total of 6300 subjects will be randomized to each group with the expectation that a total of 1642 primary endpoints will occur during a 5-year period, providing 90% power to detect the 15% relative reduction in events (alpha = 0.05) hypothesized to favor the amlodipine besylate/benazapril group. The ACCOMPLISH study will be performed in the United States and Europe. The first patient was randomizedduring 2003, and the trial should conclude in 2008.
No takes yet. Share an insight, caveat, or question.
Jamerson et al. (2004) conducted an RCT in Systolic Hypertension (n=12,600). Amlodipine besylate/benazapril vs. Benazapril/hydrochlorothiazide (force titrated to 40/12.5 mg, up to 40/25 mg) was evaluated on Composite of cardiovascular mortality and morbidity. The ACCOMPLISH trial is designed to randomize 12,600 hypertensive patients to compare amlodipine/benazapril versus benazapril/hydrochlorothiazide on cardiovascular mortality and morbidity over 5 years.
Synapse has enriched 10 related papers. Consider them for comparative context: